White Papers
Is Epsilon Healthcare a Good Opportunity?
Epsilon Healthcare's return from administration to the ASX boards is a genuine recovery story, but thin cash, related-party funding, and unresolved governance questions mean the market is still working out...
Is Epsilon Healthcare a Good Opportunity?
Epsilon Healthcare's return from administration to the ASX boards is a genuine recovery story, but thin cash, related-party funding, and unresolved governance questions mean the market is still working out...
Is Fisher & Paykel Healthcare's Tariff Playbook a Model for ANZ Medtech?
FPH's record FY26 and its tariff refund show how a disciplined ANZ medtech manufacturer absorbs trade-policy shocks, a framework worth applying across Astra Capital's healthcare coverage.
Is Fisher & Paykel Healthcare's Tariff Playbook a Model for ANZ Medtech?
FPH's record FY26 and its tariff refund show how a disciplined ANZ medtech manufacturer absorbs trade-policy shocks, a framework worth applying across Astra Capital's healthcare coverage.
Is CSL's Reset the Bottom, or the Start of a Longer Story?
CSL's FY26 result wiped US$2.6bn off the bottom line and closed out a year of guidance cuts, a CEO exit, and a delayed demerger. We use it, and a comparable...
Is CSL's Reset the Bottom, or the Start of a Longer Story?
CSL's FY26 result wiped US$2.6bn off the bottom line and closed out a year of guidance cuts, a CEO exit, and a delayed demerger. We use it, and a comparable...
Is Cochlear a Reset Opportunity or a Structural Slowdown?
After a 75% peak-to-trough drawdown and two guidance cuts, Cochlear's FY26 result beat reduced expectations. We weigh the reset case against structural China pricing risk, with a comparable stress-test against...
Is Cochlear a Reset Opportunity or a Structural Slowdown?
After a 75% peak-to-trough drawdown and two guidance cuts, Cochlear's FY26 result beat reduced expectations. We weigh the reset case against structural China pricing risk, with a comparable stress-test against...
Is Vitura Health a Turnaround in Progress, or a Value Trap?
Vitura Health is trying to re-rate from cannabis wholesaler to diversified digital health platform. We weigh the genuine progress in telehealth against three years of margin compression, leadership turnover, and...
Is Vitura Health a Turnaround in Progress, or a Value Trap?
Vitura Health is trying to re-rate from cannabis wholesaler to diversified digital health platform. We weigh the genuine progress in telehealth against three years of margin compression, leadership turnover, and...
Is Adore Beauty a Good Opportunity?
Astra Capital's investment case for ASX-listed Adore Beauty Group: why we believe the market's sharp February 2026 sell-off marks a capital allocation reset, not a demand problem. Includes original charts,...
Is Adore Beauty a Good Opportunity?
Astra Capital's investment case for ASX-listed Adore Beauty Group: why we believe the market's sharp February 2026 sell-off marks a capital allocation reset, not a demand problem. Includes original charts,...